These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 19145988)

  • 21. Treatment with metallothionein prevents demyelination and axonal damage and increases oligodendrocyte precursors and tissue repair during experimental autoimmune encephalomyelitis.
    Penkowa M; Hidalgo J
    J Neurosci Res; 2003 Jun; 72(5):574-86. PubMed ID: 12749022
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Toll-like Receptor 2 (TLR2)-related Immunopathological Responses in the Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis.
    Jafarzadeh A; Nemati M; Khorramdelazad H; Mirshafiey A
    Iran J Allergy Asthma Immunol; 2019 Jun; 18(3):230-250. PubMed ID: 31522431
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Galectin isolated from parasite inhibits remission of experimental autoimmune encephalomyelitis by up-regulating autoantibody.
    Bing SJ; Ha D; Ahn G; Cho J; Kim A; Park SK; Yu HS; Jee Y
    Clin Exp Immunol; 2015 Jun; 180(3):419-31. PubMed ID: 25619397
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recombinant human PDCD5 (rhPDCD5) protein is protective in a mouse model of multiple sclerosis.
    Xiao J; Liu W; Chen Y; Deng W
    J Neuroinflammation; 2015 Jun; 12():117. PubMed ID: 26068104
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recombinant TCR ligand induces early TCR signaling and a unique pattern of downstream activation.
    Wang C; Mooney JL; Meza-Romero R; Chou YK; Huan J; Vandenbark AA; Offner H; Burrows GG
    J Immunol; 2003 Aug; 171(4):1934-40. PubMed ID: 12902496
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immune modulation by a tolerogenic myelin oligodendrocyte glycoprotein (MOG)10-60 containing fusion protein in the marmoset experimental autoimmune encephalomyelitis model.
    Kap YS; van Driel N; Arends R; Rouwendal G; Verolin M; Blezer E; Lycke N; 't Hart BA
    Clin Exp Immunol; 2015 Apr; 180(1):28-39. PubMed ID: 25393803
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A gene therapy approach for treating T-cell-mediated autoimmune diseases.
    Chen C; Rivera A; Ron N; Dougherty JP; Ron Y
    Blood; 2001 Feb; 97(4):886-94. PubMed ID: 11159513
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CNS gene expression pattern associated with spontaneous experimental autoimmune encephalomyelitis.
    Matejuk A; Hopke C; Dwyer J; Subramanian S; Jones RE; Bourdette DN; Vandenbark AA; Offner H
    J Neurosci Res; 2003 Sep; 73(5):667-78. PubMed ID: 12929134
    [TBL] [Abstract][Full Text] [Related]  

  • 29. T cell receptor peptide therapy for autoimmune disease.
    Vandenbark AA; Chou YK; Bourdette DN; Whitham R; Hashim GA; Offner H
    J Autoimmun; 1992 Apr; 5 Suppl A():83-92. PubMed ID: 1503638
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rational design and synthesis of altered peptide ligands based on human myelin oligodendrocyte glycoprotein 35-55 epitope: inhibition of chronic experimental autoimmune encephalomyelitis in mice.
    Tselios T; Aggelidakis M; Tapeinou A; Tseveleki V; Kanistras I; Gatos D; Matsoukas J
    Molecules; 2014 Nov; 19(11):17968-84. PubMed ID: 25375337
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Endogenous T Cell Receptor Rearrangement Represses Aggressive Central Nervous System Autoimmunity in a TcR-Transgenic Model on the Non-Obese Diabetic Background.
    Yeola AP; Ignatius Arokia Doss PM; Baillargeon J; Akbar I; Mailhot B; Balood M; Talbot S; Anderson AC; Lacroix S; Rangachari M
    Front Immunol; 2019; 10():3115. PubMed ID: 32010149
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cinnamon ameliorates experimental allergic encephalomyelitis in mice via regulatory T cells: implications for multiple sclerosis therapy.
    Mondal S; Pahan K
    PLoS One; 2015; 10(1):e0116566. PubMed ID: 25569428
    [TBL] [Abstract][Full Text] [Related]  

  • 33. T cell receptor peptides in treatment of autoimmune disease: rationale and potential.
    Vandenbark AA; Hashim GA; Offner H
    J Neurosci Res; 1996 Feb; 43(4):391-402. PubMed ID: 8699526
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Early axonal damage and progressive myelin pathology define the kinetics of CNS histopathology in a mouse model of multiple sclerosis.
    Recks MS; Stormanns ER; Bader J; Arnhold S; Addicks K; Kuerten S
    Clin Immunol; 2013 Oct; 149(1):32-45. PubMed ID: 23899992
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of passive experimental autoimmune encephalomyelitis in SJL mice with a recombinant TCR ligand induces IL-13 and prevents axonal injury.
    Offner H; Subramanian S; Wang C; Afentoulis M; Vandenbark AA; Huan J; Burrows GG
    J Immunol; 2005 Sep; 175(6):4103-11. PubMed ID: 16148160
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lessons from studies of antigen-specific T cell responses in Multiple Sclerosis.
    Martin R; Bielekova B; Gran B; McFarland HF
    J Neural Transm Suppl; 2000; (60):361-73. PubMed ID: 11205154
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predicting the effects of potentially therapeutic modified peptides on polyclonal T cell populations in a mouse model of multiple sclerosis.
    Sauer EL; Trifilieff E; Greer JM
    J Neuroimmunol; 2017 Jun; 307():18-26. PubMed ID: 28495132
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Myelin-associated oligodendrocytic basic protein: identification of an encephalitogenic epitope and association with multiple sclerosis.
    Holz A; Bielekova B; Martin R; Oldstone MB
    J Immunol; 2000 Jan; 164(2):1103-9. PubMed ID: 10623862
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Therapeutic effect of a new recombinant immunotoxin mMIP-1alpha-DT390 on experimental autoimmune encephalomyelitis].
    Lü ML; Li H; Liang WB; Chen WJ; Jia Y; Li MY; Jiang ZH; Zhang L
    Nan Fang Yi Ke Da Xue Xue Bao; 2007 Jun; 27(6):775-8. PubMed ID: 17584636
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Modulation of CD4 T cell function by soluble MHC II-peptide chimeras.
    Casares S; Bona CA; Brumeanu TD
    Int Rev Immunol; 2001 Oct; 20(5):547-73. PubMed ID: 11890612
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.